#Semaglutide #PatentExpiry #RegulatoryAffairs #PharmaceuticalIndustry #DrugPricing #GLP1 #HealthcarePolicy yes, close to reality
Activation of nuclear factor-B (NF-B) results in downstream pro-inflammatory cytokine release, such as tumor necrosis factor- (TNF-), interleukin (IL)-6, and IL-1, which amplify ROS-induced myocardial stress further promoting adverse remodeling, fibrosis, and myocardial dysfunction (Jia et al., 2018)
These symptoms are primarily due to the mode of action of GLP-1 RAs on the gut, as a GLP-1 may directly or indirectly regulate electrolyte and fluid homeostasis by influencing feeding and drinking behavior as well as electrolyte transport in the kidneys and gastrointestinal tract [25]
They are FDA-approved for specific conditions, have controlled dosages, and cause minimal side effects